1 / 7

Plaque Psoriasis (Psoriasis Vulgaris) Pipeline Review H2 2015

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2015 market research report is the latest addition to RnRMarketResearch.com and its collection of Dermatology therapeutics business intelligence reports aimed to help take better decisions

anuragthakur2222
Download Presentation

Plaque Psoriasis (Psoriasis Vulgaris) Pipeline Review H2 2015

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2015 By RnRMarketResearch.com Publisher Name : Global Markets Direct Date: 30-Oct-2015 No. of Pages:249 Single User License: US $2000 Browse more Reports on Dermatology therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2015 This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2015 Companies Discussed/Mentioned in this Research: 3SBio Inc., Amgen Inc., AstraZeneca Plc, Avesthagen Limited, Avexxin AS, BIOCAD, Biocon Limited, Bionovis SA, Can-FiteBioPharma Ltd., Celgene Corporation, Celltrion, Inc., Creabilis SA, Delenex Therapeutics AG, Dermira Inc., Epirus Biopharmaceuticals, Inc., Forward Pharma A/S, Galectin Therapeutics, Inc., GenorBioPharma Co., Ltd., GlaxoSmithKline Plc, Hetero Drugs Limited, Idera Pharmaceuticals, Inc., Invion Limited, Johnson & Johnson, Kadmon Corporation, LLC, Kineta, Inc., Kyowa Hakko Kirin Co., Ltd., LEO Pharma A/S, Lipidor AB, Mabion SA, Mabtech Limited, Maruho Co., Ltd., Momenta Pharmaceuticals, Inc., Mycenax Biotech Inc., Oncobiologics, Inc., Pfizer Inc., Promius Pharma, LLC, ProtalixBioTherapeutics, Inc., Provectus Biopharmaceuticals, Inc., R-Tech Ueno, Ltd., TetraLogic Pharmaceuticals, Therapeutic Proteins International, LLC, UCB S.A. and Valeant Pharmaceuticals International, Inc. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2015 Drugs Profile Discussed in this Research: (betamethasone dipropionate + calcipotriene), (calcipotriene + betamethasone dipropionate), (calcipotriene + betamethasone), adalimumab biosimilar, AM-001, AVX-001, betamethasone valerate + maxacalcitol, bimekizumab, bleselumab, brodalumab, calcipotriene, CC-90005, CT-327, dalazatide, DFD-01, DFD-06, dimethyl fumarate, DLX-105, DNX-114, DNX-514, DRM-02, etanercept biosimilar, GK-664S, GRMD-02, GSK-2981278, guselkumab, IDP-118, IDP-122, IMO-8400, IMP-731, infliximab biobetter, infliximab biosimilar, INV-103, KD-025, LEO-32731, LP-0113, M-7040, MOL-4239, MOL-4249, pefcalcitol, PF-04965842, PF-06700841, PH-10, piclidenoson, RTU-1096, SHP-141, tofacitinib, toreforant tartrate, UCB-5857 and ustekinumab biosimilar ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2015 Scope For Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2015 • The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris) • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Plaque Psoriasis (Psoriasis Vulgaris) and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects • Coverage of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline on the basis of target, MoA, route of administration and molecule type ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris) • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  7. Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2015 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related